
12 May @ 8:00 am – 13 May @ 8:00 pm CEST
EuropaBio is supporting EFGCP Conference 2026.
Europe is at a defining moment for clinical research. The Clinical Trials Regulation set out a powerful vision: a continent united by transparency, collaboration, and efficient access to innovation. While its implementation brought both progress and pressure, it confirmed something essential—Europe’s commitment to ethics, quality, and patient protection remains unwavering.
National ethical review is a vital strength of Europe’s clinical research landscape. Ethics committees play a key role in ensuring trials uphold human dignity, scientific integrity, and public trust. Their contribution, together with the regulatory authorities’ risk-benefit review, forms the foundation of a credible and high‑quality research ecosystem. By further strengthening the collaborative partnership, Europe can achieve an ethical review process that is both protective and efficiently aligned with the needs of modern clinical research.
Today, national ethical review stands at the centre of the conference discussion. Ethics committees face growing complexity; sponsors navigate longer reviews and more information requests. These challenges highlight not failure, but opportunity: the chance to rethink how Europe aligns ethical excellence with operational efficiency.
In addition, the European Commission’s proposed new Biotech Act offers a fresh pathway—clearer roles, streamlined processes, and modern ethical standards grounded in the 2024 Declaration of Helsinki. It invites us to shape a system worthy of Europe’s innovation leadership ambitions.
The EFGCP Conference 2026 is where this work begins. Here, stakeholders from across Europe come together to share best practice experiences, challenge assumptions, and co‑create practical solutions to optimise the system. Our goal is simple and ambitious: to strengthen participant protection while enabling efficient, faster, more predictable clinical trial authorisations and start up times.
Together, we have the opportunity to build an ethical review model that reflects Europe at its best—responsible, collaborative, transparent and ready to lead the next chapter of global research.
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.